Eli Lilly has a total of 3917 patents globally, out of which 1553 have been granted. Of these 3917 patents, more than 27% patents are active. United States of America is where Eli Lilly has filed the maximum number of patents, followed by Europe and Japan, it has generated an annual revenue of $28.32 billion in the year 2021. Parallelly, USA seems to be the main focused R&D center and is also the origin country of Eli Lilly.
Eli Lilly was founded in the year 1876 by Colonel Eli Lilly, a pharmaceutical chemist and veteran of the American Civil War. Company is an American pharmaceutical firm with offices in 18 countries and headquarters in Indianapolis, Indiana. As of February 2022, Eli Lilly has a market cap of $ 227.96 Billion.
Do read about some of the most popular patents of Eli Lilly which have been covered by us in this article and also you can find Eli Lilly’ patents information, the worldwide patent filing activity and its patent filing trend over the years, and many other stats over Eli Lilly’ patent portfolio.
How many patents does the founder and the CEO of Eli Lilly have?
The founder, Eli Lilly, has 102 patents. The CEO, David A. Ricks, has 0 patents.
How many patents does Eli Lilly have?
Eli Lilly has a total of 3917 patents globally. These patents belong to 644 unique patent families. Out of 3917 patents, 1065 patents are active.
How many Eli Lilly patents are Alive/Dead?
Worldwide Patents
How Many Patents did Eli Lilly File Every Year?
Are you wondering why there is a drop in patent filing for the last two years? It is because a patent application can take up to 18 months to get published. Certainly, it doesn’t suggest a decrease in the patent filing.
| Year of Patents Filing or Grant | Eli Lilly Applications Filed | Eli Lilly Patents Granted |
| 2011 | 135 | 102 |
| 2012 | 57 | 106 |
| 2013 | 45 | 94 |
| 2014 | 98 | 95 |
| 2015 | 110 | 79 |
| 2016 | 179 | 60 |
| 2017 | 158 | 62 |
| 2018 | 132 | 32 |
| 2019 | 59 | 36 |
| 2020 | 51 | 56 |
| 2021 | 17 | 9 |
| 2022 | – | 5 |
Which Eli Lilly Drug Patents are Expiring in the Next 10 Years?
The patent no. US8435944B2 which is expiring in Sep, 2027, describes delivering a medication through the skin in sweaty areas quickly and without taking up much of the patient’s time.
Given below is the list of few drugs patented by Eli Lilly accompanied by a patent relevant to the drug which will be available for generic drug manufacturing and usage within the next/upcoming 10 years for treatment of various diseases and disorders.
| Drug Name | Patent Number | Patent Title | Patent Expiration |
| Axiron | US8435944B2 | Method and composition for transdermal… | Sep, 2027 |
| Mounjaro | US9474780B2 | GIP and GLP-1 co-agonist compounds | Jan, 2036 |
| Forteo | US7517334B2 | Medication dispensing apparatus with… | Mar, 2025 |
| Reyvow | US7423050B2 | Pyridinoylpiperidines as 5-HT1F agonists | Feb, 2028 |
| Verzenio | US7855211B2 | Protein kinase inhibitors | Dec, 2029 |
Interested in knowing about Eli Lilly’s Drug Patents Expiring in the next 10 years?
How Many Patents did Eli Lilly File in Different Countries?
Countries in which Eli Lilly Filed Patents
| Country | Patents |
| United States Of America | 466 |
| Europe | 360 |
| Japan | 290 |
| Australia | 241 |
| Canada | 195 |
| China | 150 |
| Germany | 137 |
| Hong Kong (S.A.R.) | 113 |
| Israel | 106 |
| Korea (South) | 103 |
| Mexico | 95 |
| Spain | 94 |
| Brazil | 89 |
| India | 76 |
| Austria | 70 |
| Denmark | 62 |
| Singapore | 58 |
| Portugal | 58 |
| Poland | 55 |
| New Zealand | 47 |
| South Africa | 40 |
| Norway | 40 |
| Taiwan | 39 |
| Slovenia | 36 |
| Hungary | 31 |
| Chile | 30 |
| Philippines | 28 |
| Argentina | 28 |
| Cyprus | 26 |
| Malaysia | 25 |
| Indonesia | 23 |
| Croatia | 21 |
| Czech Republic | 20 |
| Peru | 19 |
| Russia | 19 |
| Slovakia | 18 |
| Tunisia | 18 |
| Ukraine | 18 |
| Viet Nam | 16 |
| Morocco | 16 |
| Costa Rica | 15 |
| Colombia | 13 |
| Serbia | 12 |
| Ecuador | 12 |
| Jordan | 11 |
| Lithuania | 9 |
| Dominican Republic | 9 |
| United Kingdom | 8 |
| Uruguay | 8 |
| Luxembourg | 8 |
| Macao | 8 |
| El Salvador | 7 |
| Finland | 6 |
| Montenegro | 6 |
| Turkey | 6 |
| Estonia | 6 |
| Georgia | 5 |
| Greece | 5 |
| Iceland | 5 |
| Netherlands | 4 |
| Bulgaria | 4 |
| Panama | 3 |
| Kazakhstan | 3 |
| Ireland | 2 |
| Botswana | 1 |
| Egypt | 1 |
| Guatemala | 1 |
| Cuba | 1 |
| Latvia | 1 |
| Mongolia | 1 |
| Gulf Cooperation Council | 1 |
| Honduras | 1 |
| Brunei | 1 |
| Nicaragua | 1 |
| Romania | 1 |
| African Intellectual Property Organization | 1 |
| Saudi Arabia | 1 |
Where are Research Centers of Eli Lilly Patents Located?
10 Best Eli Lilly Patents
WO2005070963A1 is the most popular patent in the Eli Lilly portfolio. It has received 736 citations so far from companies like Xencor, Applied Molecular Evolution, and Immunogen.
Below is the list of 10 most cited patents of Eli Lilly:
| Publication Number | Citation Count |
| WO2005070963A1 | 736 |
| US20040002587A1 | 587 |
| WO2005113556A1 | 568 |
| US20040102804A1 | 538 |
| WO2001027160A1 | 394 |
| US6241740B1 | 364 |
| US6800620B2 | 324 |
| US6527786B1 | 320 |
| US7288096B2 | 318 |
| US20020103345A1 | 307 |
Which Companies are using Eli Lilly Patents to Advance their Research?
If patents or patents from a particular technology area of a company receive a lot of citations, it implies that the technology is being followed and incrementally innovated by the citing companies. It also indicates that citing companies are working on similar and closely related technologies.
The top citing companies in the Eli Lilly patent portfolio are Medtronic, Gilead Calistoga, and ReNeuron.
List of the top forward citing Companies –
| Company | Number of Patents |
| Medtronic | 20 |
| Gilead Calistoga | 15 |
| ReNeuron | 10 |
| Athena GTX | 10 |
| Ablynx | 9 |
| Amgen | 8 |
| National Institutes of Health | 8 |
| The University Of Chicago | 7 |
| Pf Consumer Healthcare 1 LLC | 7 |
| IBC Pharmaceuticals | 7 |
Count of 102 and 103 Type Rejections based on Eli Lilly Patents
Top Eli Lilly Patents used in Rejecting Most Patent Applications
| Patent Number | Count of Rejected Applications |
| US20040102804A1 | 12 |
| US20040002587A1 | 9 |
| US7288096B2 | 8 |
| US6610031B1 | 6 |
| US20060106038A1 | 5 |
| US20040242851A1 | 5 |
| US20100172836A1 | 4 |
| US7115716B2 | 3 |
| US7705000B2 | 3 |
| US7361763B2 | 3 |
| US20080234291A1 | 3 |
| US8071581B2 | 3 |
| US20090306348A1 | 3 |
| US20060009465A1 | 3 |
| US8562949B2 | 3 |
What Percentage of Eli Lilly US Patent Applications were Granted?
Eli Lilly (Excluding its subsidiaries) has filed 3274 patent applications at USPTO so far (Excluding Design and PCT applications). Out of these 2413 have been granted leading to a grant rate of 85.11%.
Below are the key stats of Eli Lilly patent prosecution at the USPTO.
Lilly’s major accomplishments include becoming the first business to mass-produce Jonas Salk’s polio vaccine and insulin. Prozac, Dolophine, Cymbalta , and Zyprexa are all produced by Lilly, which is presently the largest maker of psychiatric drugs.
In 2020, the need for digital health adoption accelerated, owing in part to the COVID-19 pandemic. HCPs are urging persons with chronic illnesses to use digital services such as telehealth to continue their care when social distance and stay-at-home orders are in place, for example.
In an early-stage feasibility study, Lilly collaborated with Apple, Inc. and Evidation Health to show that an iPhone, Apple Watch, iPad, and the Beddit sleep monitoring device, in combination with digital apps, can distinguish people with mild cognitive impairment (MCI) and mild Alzheimer’s disease dementia.
Migraine pain can be so severe that in a survey recently released by Eli Lilly and Company, respondents in a survey performed by Nielsen for Eli Lilly and Company rated the worst migraine pain higher than the pain associated with kidney stones and fractured bones.
There were no migraine-specific preventive medications available until recently. Existing treatments were either difficult to tolerate or ineffective for many people. With the introduction of CGRP inhibitors, this is changing. This novel medication prevents the absorption of calcitonin gene-related peptide, or CGRP, a protein linked to migraines caused by inflammation.
Which Law Firms Filed Most US Patents for Eli Lilly?
| Law Firm | Total Application | Success Rate |
| Eli Lilly And Company | 3285 | 95.77% |
| Elanco Us Inc. | 81 | 94.81% |
| Amylin Pharmaceuticals, Inc. | 119 | 79.97% |
| Goldman Sachs Bank Usa, As Collateral Agent | 52 | 97.92% |
| Sall, Daniel Jon | 51 | 100.00% |
| Audia, James E. | 50 | 97.62% |
| Astrazeneca Pharmaceuticals Lp | 41 | 82.93% |
| Sawyer, Jason Scott | 41 | 90.63% |
| Wiley, Michael Robert | 41 | 97.44% |
| Brady, Lois I. | 39 | 42.42% |
EXCLUSIVE INSIGHTS COMING SOON!
What are Eli Lilly’s key innovation segments?
What Technologies are Covered by Eli Lilly?
The chart below distributes patents filed by Eli Lilly in different countries on the basis of the technology protected in patents. It also represents the markets where Eli Lilly thinks it’s important to protect particular technology inventions.
R&D Focus: How Eli Lilly search focus changed over the years?
EXCLUSIVE INSIGHTS COMING SOON!
Interested in knowing about the areas of innovation that are being protected by Eli Lilly?
